Sales and Operational Veteran Brings Additional
Global Business Experience and Healthcare Technology Expertise to
Board
Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a
leader in transforming the pharmacy care delivery model, today
announced that the Board of Directors elected Eileen Voynick to the
Board, effective January 5, 2024. Ms. Voynick fills the vacancy
resulting from Sara J. White, a Class I director who stepped down
from the Company’s Board of Directors, effective January 5, 2024.
In addition, the Company announced that Vance Moore will not stand
for reelection to the Company’s Board at Omnicell’s 2024 annual
meeting of stockholders (the “2024 annual meeting”) and effective
as of the 2024 annual meeting, the size of the Board will be
reduced from ten to nine directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240111424299/en/
Omnicell Elects Eileen Voynick to Board
of Directors (Photo courtesy of Omnicell, Inc.)
Ms. Voynick brings over three decades of experience driving
sales and operations at global industry leaders, including in the
healthcare technology industry, at the executive and board level.
She most recently served as Chief Executive Officer of Sparta
Systems Inc., a leading provider of enterprise-quality management
software solutions. Prior to Sparta Systems, Ms. Voynick served as
Chief Operating Officer at Allscripts Healthcare Solutions, Inc.
(n/k/a Veradigm Inc., Nasdaq: MDRX), as Executive Vice President of
global sales, services, and support at Misys Healthcare Systems,
and in various management positions at Oracle, SAP, Siebel Systems,
Gartner, Ariba, and Accenture. Ms. Voynick is currently board chair
of AGS Health LLC, a revenue cycle management provider, and has
held board positions for several other organizations, including
Skydeck Acquisition Corp. (former Nasdaq: SKYAU), CDK Global, Inc.
(former Nasdaq: CDK), r3, Advanced MD Health, Jefferson Health,
Philadelphia University and Thomas Jefferson University.
“We are pleased to welcome Eileen to the Omnicell Board of
Directors,” said Randall Lipps, chairman, president, chief
executive officer, and founder of Omnicell. “Eileen is a widely
respected leader with significant experience in the software,
technology, and healthcare industries, as well as a proven track
record creating value for stockholders, accelerating growth,
driving operational excellence, and developing global businesses. I
am confident that her skills will complement and strengthen our
Board as Omnicell continues to focus on driving long-term value and
delivering outcome-centric innovations to improve patient
outcomes.”
Mr. Lipps continued, “I would like to thank Sara and Vance for
their dedication and outstanding contributions to the Board. Over
the years, they have provided valuable insights and counsel to
support Omnicell in furthering our strategy.”
“Omnicell is at the forefront of delivering mission-critical
medication management solutions, and I am honored to join the
Board,” said Ms. Voynick. “As hospitals and health systems are
relying on technology now more than ever to serve patients, I look
forward to leveraging my background in software, healthcare, and
operations and working alongside Randall and the rest of the Board
as we continue to further our innovation agenda for the benefit of
our customers and enhance stockholder value.”
Ms. Voynick has been appointed to the Board’s Corporate
Governance Committee. Following the 2024 annual meeting, the
Omnicell Board will be comprised of nine directors, eight of whom
are independent, and all of whom bring a broad range of expertise
and skills necessary to oversee and direct the Company’s business.
Six of those independent directors have been added to the Board in
the last four years.
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy
care through outcomes-centric innovation designed to optimize
clinical and business outcomes across all settings of care. Through
a comprehensive portfolio of robotics, smart devices, software, and
expert services, Omnicell solutions are helping healthcare
facilities worldwide to uncover cost savings, improve labor
efficiency, establish new revenue streams, enhance supply chain
control, support compliance, and move closer to the
industry-defined vision of the Autonomous Pharmacy. To learn more,
visit omnicell.com.
OMNICELL and the Omnicell logo are registered trademarks of
Omnicell, Inc. or one of its subsidiaries.
Forward-Looking Statements
To the extent any statements contained in this press release
deal with information that is not historical, these statements are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Without limiting the
foregoing, statements including the words “expect,” “intend,”
“may,” “will,” “should,” “would,” “could,” “plan,” “potential,”
“anticipate,” “believe,” “forecast,” “guidance,” “outlook,”
“goals,” “target,” “estimate,” “seek,” “predict,” “project,” and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are subject to the
occurrence of many events outside Omnicell’s control. Such
statements include, but are not limited to, Omnicell’s expectations
regarding the size and composition of Omnicell’s Board of
Directors. Actual results and other events may differ significantly
from those contemplated by forward-looking statements due to
numerous factors that involve substantial known and unknown risks
and uncertainties. These risks and uncertainties include, among
other things, the risks and uncertainties described in the “Risk
Factors” section of Omnicell’s most recent Annual Report on Form
10-K and Quarterly Report on Form 10-Q filed with the United States
Securities and Exchange Commission, available at www.sec.gov.
Forward-looking statements should be considered in light of these
risks and uncertainties. Investors and others are cautioned not to
place undue reliance on forward-looking statements. All
forward-looking statements contained in this press release speak
only as of the date of this press release. Omnicell assumes no
obligation to update any such statements publicly, or to update the
reasons actual results could differ materially from those expressed
or implied in any forward-looking statements, whether as a result
of changed circumstances, new information, future events, or
otherwise, except as required by law.
OMCL-E
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240111424299/en/
Kathleen Nemeth Senior Vice President, Investor Relations
Kathleen.Nemeth@omnicell.com 650-435-3318
Omnicell (NASDAQ:OMCL)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Omnicell (NASDAQ:OMCL)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024